| INTRODUCTION
The
| CLINICAL SCIENCE

| Kidney and pancreas transplantation
In the AA cohort (55 donors), the mean creatinine clearance (CrCl) was similar and there were no differences in the incidence of hypertension between those with 2 versus 0-1 risk alleles predonation and at the conclusion of follow-up. Clearly greater research is needed in this area prior to the use of risk prediction as a screening tool for potential living donor candidates.
In December 2014, a new KAS was released with expected changes in the absolute number and percentage of overall organs assigned to various subgroups on the deceased donor waiting list. Now several years in existence, several analyses were brought forward at this year's ATC. Wilk and colleagues from United Network for Organ Sharing (UNOS) presented 1-year outcomes under KAS. 5 Comparing 1-year post-KAS with the most recent 1-year pre-KAS, 1-year graft survival was similar pre-(94.08%) versus post-(93.55%), but patient survival rates post-KAS (96.16%) were statistically lower than pre-KAS (96.89%). Despite the increased number of transplantations in highly sensitized patients, patient and graft survival rates for calculated panel reactive antibodies (CPRA) 99-100% in the early post-KAS era were higher than overall rates. Although outcomes for transplantations in pediatric patients remained excellent, the significant initial decrease in overall number of organs allocated to this group, although improv- In the field of pancreas transplantation, Parajuli et al presented data on biopsies of both kidney and pancreata in simultaneous pancreas-kidney transplant (SPK) recipients, testing the assumption that allograft rejection (including type and severity) is usually concordant between organs. 10 The authors hypothesized that this assumption has led to fewer necessary pancreas biopsies and undiagnosed or incorrectly diagnosed pathology. Of the 40 pairs of biopsies studied, 25 had biopsy findings that were concordant for rejection, whereas 15
were discordant, so that rejection was present in one allograft but not the other (10 with rejection of the pancreas alone). Forty pairs of biopsies were performed. Of the 25 patients with concordant biopsy findings, 11 had rejection in both organs and 14 did not have any rejection.
Of 11 recipients with rejection in both organs, 7 had the same type of rejection: 6 showed acute cellular rejection (ACR) in both organs and 1 showed mixed rejection in both biopsies. Most striking, 4 of the 11 recipients (36%) with rejection in both organs exhibited a different type of rejection in each allograft. When clinical evidence supports the need for kidney allograft biopsy, the value of careful analysis of the pancreatic allograft even in the absence of enzyme elevation was a strong conclusion. Chinnakotla and colleagues from the University of Minnesota presented their 10-year follow-up data for 67 patients who had undergone total pancreatectomy and islet auto-transplantation (TP/IAT) for the treatment of chronic pancreatitis. 11 The 5-year and 10-year actuarial survival was 88% and 78%, respectively. The prevalence of narcotic usage declined with time (P = .001) and was 34% at 10 years. The prevalence of abdominal pain was 24%, and insulin dependence and partial graft function were seen in 17% and 33%, respectively. This led the authors to conclude that TP/IAT produces durable pain relief and improvement in quality of life parameters with at least partial islet graft function in a portion of patients beyond 10 years. Interest in this field is currently growing, and the expectation is that more presentations on islet cell transplantation (both auto-and iso-) are forthcoming at future ATC venues. Results demonstrated a 50.2% reduction in AST in NMP livers. The magnitude of this effect was greater in DCD livers than in DBD, although significant for both. Although there were much longer preservation times in the NMP group; an increased organ utilization was seen in the NMP group including organs that in the past were often discarded due to more subjective criteria as opposed to the pump and perfusate data available to clinicians (flow-dynamic, pH, lactate, bile production). Much more data are expected to soon follow these efforts.
| Liver transplantation
As with previous years, there were many presentations regarding Since 2015, access was lower or similar to HCC -for the first 6 months after listing, and higher thereafter. This is concurrent with a waitlist mortality/dropout higher or similar for HCC + patients in the first 6 months after listing and lower thereafter (P < .001). 
| Cardiothoracic transplantation
Ando et al presented an interesting analysis of the prior cardiac allocation policy and its impact on blood type O candidates. 18 A recog- 
| Pediatrics
Foster, on behalf of the TAKE-IT Investigators, presented an intervention to improve medication adherence in adolescent kidney transplant recipients. 25 TAKE-IT was the largest trial of an adherence-promoting intervention in pediatric and young adult transplant recipients, and among the largest in any age group. The trial was conducted at 8 sites in 2 countries. Eighty-one prevalent kidney transplant recipients 11-to 24-years-old were assigned to intervention and 88 to control. Adherence was electronically monitored in all participants using a multi-dose pillbox during a 3-month run-in, followed by a 12-month intervention period. 
| Regulatory
Snyder 
| Pharmacy and therapeutics
Leino et al presented a topic of ongoing clinical interest regarding intrapatient tacrolimus level variability in posttransplant recipients. 27 In clinical practice, tacrolimus is typically considered to display high During the 6-week study, daily tacrolimus troughs were obtained by home, unsupervised dry blood spots with a full pharmacokinetic (PK) profile conducted each week. Adherence was monitored by patient diary, pill counts, and medication event monitoring system (MEMS cap). Investigators found no significant differences in CV% by formulation or organ type, and tacrolimus CV% is approximately 15% in stable adherent transplant patients. The results of this investigation can be utilized to establish baseline CV% for future studies in posttransplantation patients on tacrolimus maintenance therapy. It is notable that there was a low incidence (11.3%) of treatmentemergent neutropenia during MBV treatment. An additional phase 2 double-blind, placebo-control study was presented by Vincenti on the use of ASP0113 in the prevention of CMV in mismatched kidney recipients. 29 ASP0113 is a first-in-class, nonpathogenic, plasmid vaccine designed for the prevention of CMV infection in at-risk transplant patients that is currently under development.
| Infectious disease
Study patients received 5 doses of 5 mg/ml or placebo monthly, and plasma samples were collected for CMV testing every 2 weeks from days 100-200, and then monthly through the end of the study at day 365. During this 1-year study, the proportion of patients with CMV viremia ≥1000 IU/mL was similar between patients receiving ASP0113 versus placebo (36% versus 41%; P = .307), and there were no statistically significant differences between groups for the time to experiencing first CMV viremia ≥1000 IU/ mL (P = .912) or adjudicated CMV-associated disease (P = .964).
Furthermore, there were no statistically significant differences between groups for CMV viremia at or above the lower limit of The treatment appeared safe and efficacious with significant reductions in C4d deposition and glomerular/peritubular capillaritis as well as improved graft survival in those treated with tocilizumab compared to standard of care.
| Ex vivo perfusion and organ repair
Ex vivo perfusion of donor organs is increasingly recognized as an opportunity to influence donor organ quality and potentially alter organ immunogenicity. Cellular therapy via infusion of products capable of immunomodulation or cellular repair has also arisen as a strategy to improve graft function. Poole et al shared their efforts to combine these strategies by using mesenchymal stromal cells (MSCs) to treat porcine kidneys with ischemic injury during normothermic perfusion. 36 This combination of ex vivo perfusion and MSC infusion led to a significant reduction in inflammatory cytokines and improved histology. Similarly, Dromparis and colleagues studied the molecular basis for injury and repair in ex vivo perfused porcine lungs. 37 The authors found that there was significant differential gene expression when comparing ex vivo perfusion versus cold storage. Genes related to cellular repair were only significantly upregulated in the lung grafts undergoing ex vivo perfusion compared to cold storage where genes related to injury were elevated.
| Preclinical models of allo-and xenotransplantation
Griesemer's group detailed their success with the induction of mixed chimerism in a nonhuman primate model of liver allotransplantation. 38 The investigators successfully applied a previously described strat- heterotopic heart transplant model. 40 Similar studies in allotransplantation suggest that this technique might be used as a method for early detection of graft injury or rejection. ant controls, suggesting a phenotype that could be used to identify patients for whom immunosuppression might be safely withdrawn.
| Translational trials with immunosuppression withdrawal after liver transplantation
| Costimulation blockade and immune memory
Costimulation blockade has the potential to provide targeted immunosuppression without some of the side effects associated with currently employed reagents. Pierson et al showed that combination costimulation blockade therapy with anti-CD28 and anti-CD40 antibodies more effectively attenuated rejection in a nonhuman primate heart transplant model when compared to monotherapy with either agent alone. 43 Graft histology was significantly better and evaluation of the peripheral blood by flow cytometry revealed diminished effector memory T cells in the dual-treated group. It is interesting to note that in a kidney transplant model Kawai and colleagues showed that dual costimulatory blockade failed to induce delayed tolerance despite the successful induction of transient mixed chimerism. 44 Immune memory is known to be a potential barrier to tolerance induction and may be playing a role. Chong and her group reviewed their results in a novel model in which mice are sensitized via pregnancy, and they showed that the pregnancy-induced sensitization prevented tolerance induction with costimulation blockade. 45 We know that viral infection may also play a role in the development of allo-immunity. Luo et al shared data to support this by showing that murine CMV infection at the time of transplantation can precipitate rejection and that this process is dependent on type I IFN signaling. 46 Finally, a nice presentation by Degauque and colleagues suggested that the metabolic potential of effector memory T cells, specifically CD8 + T EMRA , plays an important role in their ability to respond to IL-15 and participate in kidney transplant rejection. 47 
| BASIC SCIENCE
| Mitochondria and exosomes in graft inflammation
Graft inflammation is inherent to organ transplantation, which adversely affects transplant outcomes. Among inflammatory mediators, the subcellular structures-especially mitochondria and exosomes-have emerged as powerful inducers of graft inflammation.
Mitochondria are best known as sites where ATP production takes place in the cell to meet its energy demand. So, the pool of mitochondria often expands or contracts, depending on the metabolic status of the cell. 48 This process is tightly regulated, and failure to regulate this process usually results in cell death from either oxidative stress or energy deprivation. However, mitochondria are also capable of causing intense tissue inflammation, primarily through the release of mitochondrial DNA (mtDNA) and activation of inflammasome in the cytosol. 49 Similar to bacterial DNA, mtDNA tends to be highly methylated or oxidized, so that it acts as a potent agonist of Toll-like receptors (TLRs). Activation of the TLRs triggers proinflammatory and type I IFN responses. Mitochondria-derived reactive oxygen species (ROS) also activates the inflammasome in the cytosol, which results in production of biologically active IL-1β and IL-18, as well as induction of inflammatory cell death. 50 These events perpetuate inflammatory responses and tissue injury.
Brennan and colleagues presented exciting data showing that the vascular endothelial cells could uptake extracellular mitochondria in substantial quantities, and in doing so they became activated.
Feature of endothelial activation included production of inflammatory cytokines, chemokines, and expression of heightened levels of T cell costimulatory molecules and cell-adhesion molecules. Such activated endothelial cells then became potent stimulators of alloreactive T cells. 51 In a mouse heart transplant model, the same group demonstrated that the donor-derived mitochondria were sufficient to break allograft tolerance induced by costimulatory blockade. 52 In a different setting, Tullius's lab showed that organs from old donors released much higher levels of mtDNA than those from younger donors during ischemia reperfusion injury, which was associated with the worst graft outcomes. 53 In fact, mtDNA was as potent as CpG (an TLR9 agonist) in activating dendritic cells in vitro, thus explaining, at least partially, why elder donor grafts exhibit poor outcomes after transplantation. Furthermore, Stoltz and colleagues presented data demonstrating that in pediatric transplant patients, graft-derived cell-free DNA was readily detected in the blood of transplant recipients, and the levels of donor cell-free DNA in the circulation were closely correlated with episodes of acute cellular rejection. 54 Singh et al argued that the donor-derived circulating cell-free DNA could be a valuable biomarker for graft rejection in a pig to baboon xenotransplant model. 40 However, the exact origin of such cell-free DNA-whether it is from mitochondria or from other sources-was unclear.
Besides mitochondria, exosomes also induce prominent graft inflammation. Exosomes are extracellular vesicles, usually between 30 and 100 nm, and are actively produced by all living cells. The contents of exosomes are extremely diverse, ranging from microRNA, noncoding RNA, to proteins. 55 Evidence is accumulating that exosomes are involved in many biological processes, including coagulation, intercellular signaling, and cellular waste management. 55 In transplant models, exosomes play a key role in donor antigen presentation or donor antigen "cross-dressing" by host antigen-presenting cells (APCs). 56 Donor graft-derived exosomes are found to be outstanding biomarkers of graft rejection. 57 Studies presented by Mohanakumar's group showed that exosomes isolated from mice that rejected heart allografts triggered damage of syngeneic grafts, and that graft rejection was primarily directed against the cardiac self-antigens myosin and vimentin, 58 demonstrating that exosomes are powerful mediators of graft damage. Those studies certainly open an exciting new avenue of investigation in graft inflammation, graft damage, and tolerance resistance.
| Alloantigen "cross-dressing" in graft rejection
For decades, allograft rejection has been studied under the broad Benichou and colleagues showed that the recipient cells were also "crossed-dressed" with donor MHC molecules, and importantly, this donor alloantigen "cross-dressing" could be inhibited by nsMase 2 inhibitor, a sphingomyelase inhibitor known to inhibit exosome release, demonstrating the feasibility that this pathway can be therapeutically targeted. Indeed, a reduction of donor antigen "cross-dressing" led to prolonged allograft survival. 60 This is a very interesting area of investigation, and we will witness more exciting developments in the coming years.
| Pathways to innate allorecognition
In other models, innate immune cells, especially NK cells, can acquire features of adaptive immune cells, such as memory recall response and recognition of nonself entities. They also recognize and reject allogeneic cells in transplant settings (bone marrow and solid organ transplants) via "missing self" recognition of allogeneic nonself. 61 Evidence is accumulating that monocytes and macrophages can directly respond to allogeneic nonself. 61 This is an emerging area of investigation, and progress in this area will have enormous impact in transplantation. Lakkis and colleagues presented data that blood monocytes used the CD47/Sirpα pathway to distinguish self from allogeneic nonself. 62 CD47 is ubiquitously expressed in vivo and acts as a "don't eat me" signal. Sirpα is expressed by myeloid cells, and upon binding CD47, it transduces inhibitory signals to suppress monocytes and macrophages. 63 The authors showed that transplantation of Rag-/-γc-/-recipients. 62 As mature dendritic cells stimulate robust activation of alloreactive T cells, such innate allorecognition can contribute to allograft rejection. This is one of the examples of innate allorecognition, and will stimulate more interest in the study of other innate recognition mechanisms in graft rejection. grafts, but the kidney grafts developed extensive interstitial fibrosis and chronic rejection. 66 Data from Rowshani's group showed that in human kidney transplants with poor outcomes, CD68+ macrophages infiltrated the kidney transplants early on, and were strongly associated with graft rejection regardless of pathological classifications. 67 Furthermore, a transcriptome analysis presented by Azad et al revealed in a large cohort of human renal biopsies (1251 biopsies) that the inflammatory macrophage (M1) signature was strongly correlated to cellular rejection modules in the grafts. 68 These studies suggest an intricate role of macrophages in graft damage. These studies also call our attention on the development of therapies that specifically target innate cells in transplantation.
| A fresh look at NK cells and macrophages
| Impact of microbiota on transplant outcomes
Microbiota refers to the collection of microorganisms growing in a given individual. Based on the bacterial 16s rRNA sequencing data, the sheer number and species of microbiota are enormous, and there are orders of magnitude more microorganisms than cells in the body. 69 Under physiologic conditions, microbiota constitutes an ecosystem where diverse species of microorganisms coexist, but they are also dynamic and can be profoundly perturbed. It has been well recognized that changes in the gut microbiota influence diverse immune and inflammatory responses, ranging from obesity to autoimmune diabetes. 70 We have just begun to appreciate the complex impact of microbiota on transplant survival. Bromberg and colleague showed that the composition of gut microbiota was strikingly different among normal, pregnant (natural allograft tolerance), and colitic mice. As compared to normal or pregnant mice, the Bifidobacterium species was depleted in colitic individuals. 71 In a mouse heart transplant model where the grafts were rendered to undergo chronic rejection, feeding the recipient mice with gut microbiota from pregnant females (fecal transplant) reduced graft fibrosis and prolonged allograft survival, whereas feeding the gut microbiota from colitic mice exacerbated graft destruction. They were able to confirm that graft protection was mediated primarily by the Bifidobacterium in the gut microbiota. 71 The impact of microbiota on transplant survival was also demonstrated in other models. In a minor antigen mismatched skin transplant model, Alegre and colleagues demonstrated that the skin allografts enjoyed prolonged survival in germ-free recipients or recipients treated with oral antibiotics, but colonization of the skin grafts with
Staphylococcus epidermidis drastically accelerated graft rejection.
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Graft rejection was associated with heightened T cell priming in the draining lymph nodes. Furthermore, Wu and colleagues presented data showing that in a mouse kidney transplant model, treatment with the gut microbial metabolite sodium acetate (short chain fatty acid product) significantly extended the kidney allograft survival. 73 These studies raised an interesting prospect that manipulation of microbiota could be therapeutically valuable in improving transplant outcomes. Treg-specific deletion of p27kip. 75 Moreover, Briscoe and colleagues showed that an adaptor protein called TSAd was critically important in Foxp3+ Treg functions, and that its absence impaired tolerance induction in a minor antigen-mismatched heart transplant model. 76 TSAd interacts with Lck, a key signaling molecule downstream of the T cell receptor, and promotes auto-phosphorylation of lck. This is an interesting area of investigation and certainly deserves further attention.
| New insights into regulation of Foxp3+ Tregs
In terms of features of T effector cells that are suppressed by Foxp3+ Tregs, LeGuern and colleagues presented studies that T effector cells must acquire intact self MHC class II molecules from APCs in order to gain susceptibility to Foxp3+ Treg-mediated suppression. 77 The transfer of MHC class II molecules occurred in an inflammatory milieu, and the transferred molecules served as a "suppress-me-signal" and were recognized by the TCR on Foxp3+ Tregs. 77 This is an interesting model, but whether this is a universal mechanism or only confined to the specific experimental conditions in the study deserves further clarification. In lung transplant patients in the clinic, bronchiolitis obliterans syndrome (or BOS) is a major complication that limits graft survival in the long-term. Brosseau and colleagues showed that one of the striking differences between patients that developed BOS and those that did not was the frequency of transitional B cells in the circulation. 80 Patients with a high percentage of transitional B cells exhibited better graft outcomes, but those without transitional B cells developed BOS early after transplantation. These data also support the proposition that B cell subsets could also be valid biomarkers in transplantation. 80 Like many other studies, whether changes in B cell phenotypes are consequences or mechanisms of graft survival remains unknown.
| Other regulatory cell types in transplant survival
| Tissue complementation and xenotransplantation
Donor shortage presents a unique set of challenges to the transplant community, and the pursuit of xenotransplantation remains vigorous.
The recent advances in gene-editing technology (eg, CRISPR/Cas9) generated additional excitement in the field. One area of excitement is the creation of chimeric organs through xenogeneic tissue complementation by introducing xenogeneic stem cells into developing embryos. 81 For example, mouse stem cells can be introduced into developing rat embryos, which are genetically modified to inhibit the native pancreatic islet development. Thus pancreas in such rats consists of rat exocrine tissues and mouse endocrine tissues, and such tissue can reverse diabetes in diabetic mice following transplantation. 81 In a different study, Oldani and colleagues presented data showing that xenogeneic liver repopulated with autologous hepatocytes provided liver functions and supported host survival, 82 providing a proof of concept about this chimeric tissue approach in xenotransplantation. that otherwise would be difficult to study. This approach will make its way to the mainstream of immunology research.
| Emerging approaches and technologies
Nanomedicine combines advanced material science and biotechnology, and promises to deliver significant impact in the field of organ transplantation, especially in the areas of drug delivery, tissue regeneration, and graft prognosis. 85 Studies presented by Abdi group showed that immunosuppressive drugs could be packaged in nanoparticles and selectively delivered to the graft-draining lymph nodes where T cell priming occurred. This site-specific drug delivery was accomplished by designing nanoparticles with a guiding antibody that specifically recognizes the high endothelial venues in the host draining lymph nodes. 86 This approach substantially extended allograft survival without systemic exposure of the immunosuppressive drugs in transplant recipients. With advanced nanomaterials and sophisticated design of nanoparticles and nanosensors, 85 nanotechnology appears to be poised to substantially advance transplant science.
| CONCLUSIONS
Abstracts highlighted here provide only a glimpse of the science presented at the meeting and remind us of the key issues and ongoing challenges facing the field. The ATC remains one of the most important meetings for reporting advances in the field of transplantation, and next year's meeting in Seattle should provide an excellent venue for scientific discussion and debate.
